Generic Medicine Info
Indications and Dosage
Ocular inflammation
Adult: As 1% suspension: Apply 1 drop into the conjunctival sac of the affected eye ≥4 times daily. Treatment duration should not be >4 wk.

Anterior uveitis
Adult: As 1% suspension: Apply 1-2 drops into the conjunctival sac of the affected eye during waking hr, hourly for the 1st wk, every 2 hrly during the 2nd wk, 4 times daily during the 3rd wk, bid during the 1st 4 days of 4th wk and then once daily during the last 3 days of the 4th wk.

Postoperative ocular inflammation
Adult: Apply 1-2 drops into the conjunctival sac of the affected eye 4 times daily for 2 wk, starting 24 hr after surgery.
Epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, viral diseases of the cornea and conjunctiva, mycobacterial, fungal or amoebic infection of the eye; acute purulent untreated infections which may be masked or enhanced by the use of the steroid; undiagnosed red eye.
Special Precautions
Temporary, blurred vision may occur immediately after admin, do not drive or operate machinery if affected. Re-evaluate if sign and symptoms do not improve after 2 days and monitor intraocular pressure if used ≥10 days. For ophthalmic use only, not to be used as inj. Shake well before use. Pregnancy.
Adverse Reactions
Blurring of vision, discharge, eye pain and discomfort, foreign body sensation, hyperaemia, pruritus, thinning of the cornea and sclera. Prolonged use may result in ocular hypertension, glaucoma, optic nerve damage, visual acuity and visual fields defects, formation of posterior subcapsular cataract and secondary ocular infections.
In topical overdose, rinse eye with lukewarm water.
Description: Rimexolone is a topical corticosteroid used to treat inflammatory eye disorders.
Metabolism: Undergoes extensive hepatic metabolism. Half-life: 1-2 hr.
Excretion: Excretion via faeces.
Store upright between 36-77°F (2-25°C), do not freeze.
MIMS Class
Eye Corticosteroids
Disclaimer: This information is independently developed by MIMS based on Rimexolone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in